Clinical Trial Update: Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease [Phase 2]

View source ↗

Summary

Regeneron is sponsoring a Phase 2 clinical trial to assess ANGPTL3 inhibition in adults with diabetic kidney disease, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Kidney Disease

Drugs mentioned

• ANGPTL3 inhibitor

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Diabetic Kidney Disease (DKD) | Phase 2 | Status: RECRUITING